{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,16]],"date-time":"2025-12-16T12:20:28Z","timestamp":1765887628548},"reference-count":20,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2014,7,24]],"date-time":"2014-07-24T00:00:00Z","timestamp":1406160000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pediatric Dermatology"],"published-print":{"date-parts":[[2015,1]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Cyclosporine is a systemic therapy used for control of severe atopic dermatitis (<jats:styled-content style=\"fixed-case\">AD<\/jats:styled-content>) in children. Although traditionally recommended at a dose of 5\u00a0mg\/kg\/day for 6\u00a0months, a longer duration of treatment may be necessary to bring a child with active and severe disease into remission. There are few data on the short\u2010 and long\u2010term effectiveness of longer courses of therapy. This was a retrospective chart review of children treated with cyclosporine at a Canadian hospital\u2010affiliated clinic between 2000 and 2013. Fifteen patients with adequate follow\u2010up were identified. Twelve (80%) were male and the mean age at initiation of cyclosporine was 11.2\u00a0\u00b1\u00a03.4\u00a0years. The mean duration of cyclosporine therapy was 10.9\u00a0\u00b1\u00a02.7\u00a0months (range 7\u201315 months) at a starting dose of 2.8\u00a0\u00b1\u00a00.6\u00a0mg\/kg\/day. Of 12 patients (80%) who responded to cyclosporine, 5 patients (42%) had relapsed at a follow\u2010up of 22.7\u00a0\u00b1\u00a015.0\u00a0months. The duration of therapy was longer in patients who did not relapse (17.7\u00a0\u00b1\u00a010.7 months) than in those who did (10.2\u00a0\u00b1\u00a02.7 months) (p\u00a0=\u00a00.06). Adverse events led to discontinuation in three patients (20%) and included infection\u2010related complications in two patients and reversible renal toxicity in one. These results suggest that a longer duration of low\u2010dose cyclosporine may help decrease the risk of relapse in patients with severe <jats:styled-content style=\"fixed-case\">AD<\/jats:styled-content> who are resistant to topical therapies.<\/jats:p>","DOI":"10.1111\/pde.12367","type":"journal-article","created":{"date-parts":[[2014,7,25]],"date-time":"2014-07-25T03:41:04Z","timestamp":1406259664000},"page":"36-40","source":"Crossref","is-referenced-by-count":26,"title":["Retrospective Review of Relapse after Systemic Cyclosporine in Children with Atopic Dermatitis"],"prefix":"10.1111","volume":"32","author":[{"given":"Cathryn","family":"Sibbald","sequence":"first","affiliation":[{"name":"Department of Dermatology University of Toronto Toronto Ontario Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elena","family":"Pope","sequence":"additional","affiliation":[{"name":"Department of Dermatology University of Toronto Toronto Ontario Canada"},{"name":"Section of Dermatology Hospital for Sick Children Toronto Ontario Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nhung","family":"Ho","sequence":"additional","affiliation":[{"name":"Department of Dermatology University of Toronto Toronto Ontario Canada"},{"name":"Section of Dermatology Hospital for Sick Children Toronto Ontario Canada"},{"name":"Schulich School of Medicine University of Western Ontario London Ontario Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Miriam","family":"Weinstein","sequence":"additional","affiliation":[{"name":"Department of Dermatology University of Toronto Toronto Ontario Canada"},{"name":"Section of Dermatology Hospital for Sick Children Toronto Ontario Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2014,7,24]]},"reference":[{"key":"e_1_2_5_2_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1399-3038.2010.01064.x"},{"key":"e_1_2_5_3_1","doi-asserted-by":"publisher","DOI":"10.1542\/peds.2007-2232"},{"key":"e_1_2_5_4_1","first-page":"1158","article-title":"Management of severe atopic dermatitis in children","volume":"11","author":"Tan A","year":"2012","journal-title":"J Drugs Dermatol"},{"key":"e_1_2_5_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2010.02.063"},{"key":"e_1_2_5_6_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1468-3083.2006.02023.x"},{"key":"e_1_2_5_7_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2133.2000.03241.x"},{"key":"e_1_2_5_8_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.1995.tb08633.x"},{"key":"e_1_2_5_9_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1468-3083.1998.tb00976.x"},{"key":"e_1_2_5_10_1","doi-asserted-by":"publisher","DOI":"10.1159\/000051694"},{"key":"e_1_2_5_11_1","doi-asserted-by":"publisher","DOI":"10.2165\/00003495-200969030-00005"},{"key":"e_1_2_5_12_1","doi-asserted-by":"publisher","DOI":"10.5021\/ad.2010.22.1.9"},{"key":"e_1_2_5_13_1","doi-asserted-by":"publisher","DOI":"10.1034\/j.1399-3038.2001.012004216.x"},{"key":"e_1_2_5_14_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1398-9995.2009.02054.x"},{"key":"e_1_2_5_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2010.04.032"},{"key":"e_1_2_5_16_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.1993.tb15154.x"},{"key":"e_1_2_5_17_1","doi-asserted-by":"crossref","first-page":"168","DOI":"10.2340\/0001555575168","article-title":"Permanent remission of severe atopic dermatitis in a Chinese patient after cyclosporin A therapy","volume":"75","author":"Wong SS","year":"1995","journal-title":"Acta Derm Venereol"},{"key":"e_1_2_5_18_1","first-page":"773","article-title":"A retrospective analysis of cyclosporine dose regimens and contributing factors for relapse in atopic dermatitis","volume":"50","author":"Roh HS","year":"2012","journal-title":"Korean J Dermatol"},{"key":"e_1_2_5_19_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1523-1747.2003.12040.x"},{"key":"e_1_2_5_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0190-9622(96)90281-9"},{"key":"e_1_2_5_21_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.1996.tb00705.x"}],"container-title":["Pediatric Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fpde.12367","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/pde.12367","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T20:52:17Z","timestamp":1696193537000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/pde.12367"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,7,24]]},"references-count":20,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2015,1]]}},"alternative-id":["10.1111\/pde.12367"],"URL":"https:\/\/doi.org\/10.1111\/pde.12367","archive":["Portico"],"relation":{},"ISSN":["0736-8046","1525-1470"],"issn-type":[{"value":"0736-8046","type":"print"},{"value":"1525-1470","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,7,24]]}}}